PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16534015-12	2006	CONCLUSIONS: This analysis of 1-year data collected by the e-Cypher registry suggests a high degree of safety of SES, with a rate of stent thrombosis similar to that observed in randomized trials.	ses	113-116	LIM domain binding 3	Homo sapiens	61-67	
22008318-2	2012	METHODS AND RESULTS: The Cypher Post-Marketing Surveillance Registry study has been conducted since August 2004 in Japan to evaluate the efficacy and safety of SES in a real-world setting.	ses	160-163	LIM domain binding 3	Homo sapiens	25-31	
17434617-1	2008	OBJECTIVE: This post-marketing surveillance registry is aimed at determining the safety and reliability of the CYPHER Select Sirolimus-eluting stent (SES) in routine clinical practice.	ses	150-153	LIM domain binding 3	Homo sapiens	111-117	
17434617-2	2008	BACKGROUND: Little information and angiographic follow-up data in large-scale "real world" registry is available for the CYPHER Select SES, an advanced-generation SES.	ses	135-138	LIM domain binding 3	Homo sapiens	121-127	
17434617-2	2008	BACKGROUND: Little information and angiographic follow-up data in large-scale "real world" registry is available for the CYPHER Select SES, an advanced-generation SES.	ses	163-166	LIM domain binding 3	Homo sapiens	121-127	
17434617-9	2008	Angiographic follow-up at 9 months was performed in 418 (68.3%) lesions treated by CYPHER Select SES.	ses	97-100	LIM domain binding 3	Homo sapiens	83-89	
17434617-14	2008	The safety and efficacy of CYPHER Select SES shown in this registry are consistent with those seen in SES studies.	ses	41-44	LIM domain binding 3	Homo sapiens	27-33	
12866772-2	2003	From a recent study, the sirolimus eluting stent (SES) (CYPHER, Cordis, Johnson & Johnson) appear to demonstrate a remarkable efficacy and safety in preventing restenosis.	ses	50-53	LIM domain binding 3	Homo sapiens	56-62